ECSP12012310A - 5-fluoro-1h-pirazolopiridinas sustituidas y su uso - Google Patents
5-fluoro-1h-pirazolopiridinas sustituidas y su usoInfo
- Publication number
- ECSP12012310A ECSP12012310A ECSP12012310A ECSP12012310A EC SP12012310 A ECSP12012310 A EC SP12012310A EC SP12012310 A ECSP12012310 A EC SP12012310A EC SP12012310 A ECSP12012310 A EC SP12012310A
- Authority
- EC
- Ecuador
- Prior art keywords
- fluoro
- pirazolopiridines
- replaced
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente solicitud se refiere a nuevas 5-fluoro-1H-pirazolopiridinas sustituidas, a procedimientos para su preparación, a su uso solas o en combinaciones para el tratamiento y/o prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o prevención de enfermedades, en especial para el tratamiento y/o prevención de enfermedades cardiocirculatorias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010021637A DE102010021637A1 (de) | 2010-05-26 | 2010-05-26 | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12012310A true ECSP12012310A (es) | 2012-12-28 |
Family
ID=44119218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12012310 ECSP12012310A (es) | 2010-05-26 | 2012-11-26 | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso |
Country Status (45)
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
PE20180203A1 (es) | 2009-11-27 | 2018-01-31 | Adverio Pharma Gmbh | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico |
EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN106977530A (zh) | 2010-07-09 | 2017-07-25 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
CA2833698A1 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
PL2896617T3 (pl) | 2011-11-25 | 2017-07-31 | Adverio Pharma Gmbh | Sposób wytwarzania podstawionych (z)-alfa-fluoro-beta-amino-akryloaldehydów |
CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
DE102012200349A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
JP6140738B2 (ja) | 2012-03-06 | 2017-05-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アザ二環およびその使用 |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
AU2013292046C1 (en) | 2012-07-20 | 2018-03-15 | Bayer Pharma Aktiengesellschaft | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
AU2013353117A1 (en) | 2012-11-30 | 2015-06-04 | Astellas Pharma Inc. | Imidazopyridine compound |
SG11201506211RA (en) | 2013-02-21 | 2015-09-29 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
SG11201505974VA (en) | 2013-03-01 | 2015-09-29 | Bayer Pharma AG | Trifluormethyl-substituted ring-fused pyrimidines and use thereof |
CN105473570A (zh) | 2013-06-21 | 2016-04-06 | 拜耳制药股份公司 | 二氨基杂芳基取代的吡唑 |
WO2015004105A1 (de) | 2013-07-10 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Benzyl-1h-pyrazolo[3,4-b]pyridine und ihre verwendung |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
US20160221965A1 (en) | 2013-09-16 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluoromethyl pyrimidinones and their use |
MX2016004250A (es) | 2013-10-07 | 2016-07-12 | Bayer Pharma AG | Tienouracilcarboxamidas ciclicas y usos de las mismas. |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
CN106458938A (zh) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 |
CA2944614A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
CN107074783B (zh) | 2014-11-03 | 2020-06-05 | 拜耳制药股份公司 | 羟烷基取代的苯基三唑衍生物及其用途 |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
EP3291811B1 (en) | 2015-05-06 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
GEP20207104B (en) | 2015-12-10 | 2020-05-11 | Bayer Pharma AG | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
US10414765B2 (en) | 2015-12-10 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
EP3389655A2 (en) | 2015-12-14 | 2018-10-24 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
CN105461715B (zh) * | 2015-12-15 | 2017-03-29 | 郑州大明药物科技有限公司 | 一种利奥西呱中间体的合成方法 |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017121692A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte sulfamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
AR108265A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Derivados de feniltriazol sustituidos con amida y usos de estos |
EP3452457B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
EP3458063A4 (en) | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHODS OF USING TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR FIBROTIC DISORDERS |
CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
US20200016159A1 (en) | 2016-09-23 | 2020-01-16 | Bayer Aktiengesellschaft | N3-cyclically substituted thienouracils and use thereof |
CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
EP3525779A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
WO2018073144A1 (en) | 2016-10-20 | 2018-04-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
WO2018153899A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
JP7107963B2 (ja) | 2017-04-10 | 2022-07-27 | バイエル・アクチエンゲゼルシヤフト | 置換されたn-アリールエチル-2-アリールキノリン-4-カルボキサミド類及びそれの使用 |
CN108690016B (zh) * | 2017-04-11 | 2022-08-12 | 广东东阳光药业有限公司 | 吡唑并吡啶类化合物及其用途 |
US11242335B2 (en) | 2017-04-11 | 2022-02-08 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
EP3700898A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
US11173151B2 (en) | 2017-10-24 | 2021-11-16 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
PL3700913T3 (pl) | 2017-10-24 | 2022-02-21 | Bayer Aktiengesellschaft | Proleki podstawionych pochodnych triazolu i ich zastosowania |
CR20200173A (es) * | 2017-10-24 | 2020-06-26 | Bayer Pharma AG | Amidas de imidazopiridina sustituidas y su uso |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
EP3700897A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081299A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CA3081775A1 (en) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same |
MX2020005646A (es) | 2017-12-01 | 2020-08-20 | Bayer Pharma AG | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. |
JP7337067B2 (ja) * | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
CN112055584A (zh) * | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
EP3566704A1 (en) | 2018-05-11 | 2019-11-13 | Bayer Aktiengesellschaft | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
SG11202011018PA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
US20220324865A1 (en) | 2018-05-17 | 2022-10-13 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
MX2021000363A (es) | 2018-07-11 | 2021-04-29 | Cyclerion Therapeutics Inc | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CA3107169A1 (en) | 2018-07-24 | 2020-01-30 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
EP3826619A1 (de) | 2018-07-24 | 2021-06-02 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
MA54275A (fr) | 2018-11-27 | 2022-03-02 | Bayer Ag | Procédé de fabrication de formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires |
CA3123360A1 (en) | 2018-12-17 | 2020-06-25 | Adverio Pharma Gmbh | Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
CN114585637A (zh) | 2019-05-07 | 2022-06-03 | 拜耳公司 | Masp抑制化合物及其用途 |
WO2020245342A1 (en) | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
JP2023500263A (ja) | 2019-11-06 | 2023-01-05 | バイエル・アクチエンゲゼルシヤフト | アドレナリン受容体adrac2の阻害剤 |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
CA3169671A1 (en) | 2020-02-03 | 2021-08-12 | Adverio Pharma Gmbh | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
CA3170507A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
US20230083417A1 (en) | 2020-02-26 | 2023-03-16 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
EP3925953A1 (en) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
EP4240750A1 (en) | 2020-11-04 | 2023-09-13 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
WO2022122916A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
AU2021398486A1 (en) | 2020-12-10 | 2023-06-22 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
JP2023552583A (ja) | 2020-12-10 | 2023-12-18 | バイエル・アクチエンゲゼルシヤフト | 置換されたピラゾロピペリジンカルボン酸類 |
EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
WO2022225903A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
TW202308634A (zh) | 2021-04-20 | 2023-03-01 | 美商賽克瑞恩醫療公司 | 使用sGC刺激劑之CNS疾病治療 |
WO2023034364A1 (en) | 2021-08-31 | 2023-03-09 | Teva Pharmaceuticals International Gmbh | Solid state forms of vericiguat and process for preparation thereof |
WO2023126437A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
TW202342035A (zh) | 2021-12-29 | 2023-11-01 | 德商拜耳廠股份有限公司 | 醫藥乾粉吸入配製物 |
AR128147A1 (es) | 2021-12-29 | 2024-03-27 | Bayer Ag | Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo |
ES2956054A1 (es) * | 2022-05-03 | 2023-12-12 | Moehs Iberica Sl | 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01198481A (ja) * | 1988-02-01 | 1989-08-10 | Canon Inc | マイクロ波プラズマcvd法による堆積膜形成法 |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
EP0463754A1 (en) | 1990-06-25 | 1992-01-02 | Rohm And Haas Company | Stabilization of glutarimide polymers |
DK181190D0 (da) | 1990-07-30 | 1990-07-30 | Lundbeck & Co As H | 3-aryl-indol- eller 3-aryl-indazolderivater |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
HUP0001115A3 (en) | 1996-10-14 | 2001-06-28 | Bayer Ag | Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same |
US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
IL135462A0 (en) | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
JP4295505B2 (ja) | 2000-11-22 | 2009-07-15 | バイエル アクチェンゲゼルシャフト | 新規なラクタム置換ピラゾロピリジン誘導体 |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
GR1004350B (el) * | 2002-03-29 | 2003-09-26 | Συσκευη εισπνοων ξηρης σκονης | |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
DE10242941A1 (de) | 2002-09-16 | 2004-03-18 | Bayer Ag | Substituiertes Pyrazolderivat |
DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
DK1564210T5 (da) | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer |
DE602004029025D1 (de) | 2003-05-09 | 2010-10-21 | Asahi Glass Co Ltd | Verfahren zur herstellung von 3-substituiertem 2-chlor-5-fluorpyridin bzw. einem salz davon |
WO2005030121A2 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
CN100355732C (zh) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
GB0403819D0 (en) | 2004-02-20 | 2004-03-24 | Merck Sharp & Dohme | New compounds |
US7514463B2 (en) | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
CA2583073A1 (en) | 2004-10-05 | 2006-04-13 | Bayer Healthcare Ag | A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction |
DE102005047945A1 (de) | 2005-07-16 | 2007-01-18 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen |
US20100016305A1 (en) | 2005-07-18 | 2010-01-21 | Bayer Healthcare Ag | novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
JP5588339B2 (ja) | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化学化合物 |
AU2008282156B2 (en) | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2009145814A2 (en) | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
AR077898A1 (es) | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
UY33040A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
PE20180203A1 (es) | 2009-11-27 | 2018-01-31 | Adverio Pharma Gmbh | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico |
JP5960061B2 (ja) | 2009-12-18 | 2016-08-02 | エクソドス ライフ サイエンシーズ リミテッド パートナーシップ | 末梢血管疾患を治療するための方法および組成物 |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
NZ603799A (en) * | 2010-05-26 | 2014-10-31 | Bayer Ip Gmbh | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN106977530A (zh) | 2010-07-09 | 2017-07-25 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010040234A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
WO2012166390A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
EP2751106B1 (de) | 2011-09-02 | 2017-10-18 | Bayer Intellectual Property GmbH | Substituierte annellierte pyrimidine und ihre verwendung |
PL2896617T3 (pl) | 2011-11-25 | 2017-07-31 | Adverio Pharma Gmbh | Sposób wytwarzania podstawionych (z)-alfa-fluoro-beta-amino-akryloaldehydów |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
-
2010
- 2010-05-26 DE DE102010021637A patent/DE102010021637A1/de not_active Withdrawn
-
2011
- 2011-05-19 UY UY0001033396A patent/UY33396A/es active IP Right Grant
- 2011-05-19 US US13/111,856 patent/US8420656B2/en active Active
- 2011-05-24 ES ES11720806.6T patent/ES2567795T3/es active Active
- 2011-05-24 SG SG2012082152A patent/SG185460A1/en unknown
- 2011-05-24 CA CA2800697A patent/CA2800697C/en active Active
- 2011-05-24 JO JOP/2011/0171A patent/JO3199B1/ar active
- 2011-05-24 PE PE2012002172A patent/PE20130402A1/es active IP Right Grant
- 2011-05-24 WO PCT/EP2011/058431 patent/WO2011147809A1/de active Application Filing
- 2011-05-24 PL PL11720806T patent/PL2576547T3/pl unknown
- 2011-05-24 RS RS20160263A patent/RS54704B1/en unknown
- 2011-05-24 BR BR112012030010-5A patent/BR112012030010A2/pt not_active Application Discontinuation
- 2011-05-24 KR KR1020127033601A patent/KR101862420B1/ko active IP Right Grant
- 2011-05-24 NZ NZ603800A patent/NZ603800A/en unknown
- 2011-05-24 BR BR122020023470-9A patent/BR122020023470B1/pt active IP Right Grant
- 2011-05-24 CN CN201180026010.7A patent/CN102939289B/zh active Active
- 2011-05-24 MY MYPI2012700999A patent/MY164356A/en unknown
- 2011-05-24 UA UAA201214902A patent/UA109660C2/uk unknown
- 2011-05-24 EP EP11720806.6A patent/EP2576547B1/de active Active
- 2011-05-24 AU AU2011257335A patent/AU2011257335B2/en active Active
- 2011-05-24 MA MA35391A patent/MA34248B1/fr unknown
- 2011-05-24 CU CU2012000161A patent/CU24086B1/es active IP Right Grant
- 2011-05-24 HU HUE11720806A patent/HUE026912T2/en unknown
- 2011-05-24 AR ARP110101777A patent/AR081628A1/es active IP Right Grant
- 2011-05-24 DK DK11720806.6T patent/DK2576547T3/en active
- 2011-05-24 EA EA201291336A patent/EA023631B9/ru not_active IP Right Cessation
- 2011-05-24 JP JP2013511643A patent/JP5896991B2/ja active Active
- 2011-05-24 MX MX2012013324A patent/MX2012013324A/es active IP Right Grant
- 2011-05-24 SI SI201130781A patent/SI2576547T1/sl unknown
- 2011-05-24 ME MEP-2016-64A patent/ME02393B/me unknown
- 2011-05-25 TW TW100118222A patent/TWI516263B/zh active
-
2012
- 2012-11-15 IL IL223050A patent/IL223050A/en active IP Right Grant
- 2012-11-16 CO CO12208156A patent/CO6640226A2/es active IP Right Grant
- 2012-11-20 CL CL2012003226A patent/CL2012003226A1/es unknown
- 2012-11-21 GT GT201200313A patent/GT201200313A/es unknown
- 2012-11-23 TN TNP2012000549A patent/TN2012000549A1/en unknown
- 2012-11-23 DO DO2012000299A patent/DOP2012000299A/es unknown
- 2012-11-26 EC ECSP12012310 patent/ECSP12012310A/es unknown
- 2012-11-26 CR CR20120596A patent/CR20120596A/es unknown
-
2013
- 2013-03-27 US US13/851,373 patent/US8921377B2/en active Active
- 2013-08-15 HK HK13109548.3A patent/HK1182112A1/zh unknown
-
2014
- 2014-11-24 US US14/552,122 patent/US9266885B2/en active Active
-
2016
- 2016-01-15 US US14/996,678 patent/US20160129004A1/en not_active Abandoned
- 2016-04-11 HR HRP20160370TT patent/HRP20160370T1/hr unknown
- 2016-04-12 CY CY20161100301T patent/CY1117372T1/el unknown
- 2016-11-10 US US15/348,545 patent/US9993476B2/en active Active
- 2016-12-20 IL IL249669A patent/IL249669B/en active IP Right Grant
-
2018
- 2018-05-16 US US15/981,598 patent/US10736896B2/en active Active
-
2020
- 2020-07-02 US US16/919,385 patent/US11439642B2/en active Active
-
2021
- 2021-08-26 LT LTPA2021518C patent/LTC2576547I2/lt unknown
- 2021-08-27 HU HUS2100032C patent/HUS2100032I1/hu unknown
- 2021-08-30 FR FR21C1038C patent/FR21C1038I2/fr active Active
- 2021-09-06 NO NO2021032C patent/NO2021032I1/no unknown
- 2021-12-01 NL NL301146C patent/NL301146I2/nl unknown
-
2022
- 2022-08-18 US US17/820,667 patent/US20220409618A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
UY35115A (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
DOP2011000285A (es) | 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso | |
UY34918A (es) | Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
ECSP13012379A (es) | Pirimidinas y triazinas condensadas y su uso | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
ECSP10010494A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
UY35652A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
CU20100183A7 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
CU20100260A7 (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
CU20150047A7 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas | |
HN2010001125A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso |